ARCHIVES

Conversation With The Cancer Letter: How ASCO’s Guideline Differs—And Why

This article is from The Cancer Letter archive.

Vol. 38 No. 29 | July 20, 2012

Download PDF Visit The Full Archive

Related Articles

Fewer Young Scientists win NIH Grants, Study

September 30, 1994

In Brief: Georgetown Professor Heads Cancer Therapy Evaluation Program; NCI-VA Branch Abolished

September 7, 1979

McKenna Sees Budget Cuts as Threat to Year 2000 Goals Urges Stepped Up Efforts Against Tobacco Industry

April 5, 1985

Cancer Rates May Rise 50% By 2020, IARC Says

April 18, 2003

Phase III Nexavar Trial Fails Primary Endpoint

August 29, 2014

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

May 31, 2013